Dovato 50 mg/300 mg film-coated tablets
*Company:
ViiV Healthcare UK LtdStatus:
UpdatedLegal Category:
Product subject to restricted prescription (C)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 04 November 2024
File name
ie-spc-dovato-issue19draft1-clean-no headers.pdf
Reasons for updating
- Change to section 4.6 - Pregnancy and lactation
- Change to section 10 - Date of revision of the text
Legal category:Product subject to restricted prescription (C)
Updated on 04 November 2024
File name
ie-pl-dovato-issue15draft1-clean-no headers.pdf
Reasons for updating
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 6 - date of revision
Updated on 06 August 2024
File name
ie-pl-dovato-issue14draft1-clean-no headers.pdf
Reasons for updating
- Change to section 3 - how to take/use
- Change to section 4 - how to report a side effect
- Change to section 6 - what the product contains
- Change to section 6 - date of revision
Updated on 02 August 2024
File name
ie-spc-dovato-issue18draft1-clean-noheaders.pdf
Reasons for updating
- Change to section 6.3 - Shelf life
- Change to section 10 - Date of revision of the text
Legal category:Product subject to restricted prescription (C)
Updated on 02 August 2024
File name
ie-spc-dovato-issue18draft1-clean-no headers.pdf
Reasons for updating
- Change to section 6.3 - Shelf life
- Change to section 10 - Date of revision of the text
Legal category:Product subject to restricted prescription (C)
Updated on 05 July 2024
File name
ie-spc-dovato-issue17draft1-clean-no headers.pdf
Reasons for updating
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 10 - Date of revision of the text
Legal category:Product subject to restricted prescription (C)
Updated on 05 July 2024
File name
ie-pl-dovato-issue13draft1-clean-noheaders.pdf
Reasons for updating
- Change to section 4 - how to report a side effect
Updated on 28 March 2024
File name
ieukni-pl-dovato-issue12draft1-clean-no headers.pdf
Reasons for updating
- Change to section 2 - use in children and adolescents
- Change to section 2 - excipient warnings
Updated on 28 March 2024
File name
ieukni-spc-dovato-issue16draft1-clean-no headers.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
Legal category:Product subject to restricted prescription (C)
Updated on 08 September 2023
File name
ieukni-pl-dovato-issue11draft1-clean no headers.pdf
Reasons for updating
- Change to section 5 - how to store or dispose
- Change to section 6 - what the product looks like and pack contents
- Change to section 6 - marketing authorisation number
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
Blister pack update
Updated on 08 September 2023
File name
ieukni-spc-dovato-issue15draft1-clean-no headers.pdf
Reasons for updating
- Change to section 6.3 - Shelf life
- Change to section 6.5 - Nature and contents of container
- Change to section 8 - Marketing authorisation number(s)
- Change to section 10 - Date of revision of the text
Legal category:Product subject to restricted prescription (C)
Free text change information supplied by the pharmaceutical company
Blister pack update
Updated on 08 September 2023
File name
ieukni-pl-dovato-issue11draft1-clean.pdf
Reasons for updating
- Change to section 5 - how to store or dispose
- Change to section 6 - what the product looks like and pack contents
- Change to section 6 - marketing authorisation number
- Change to section 6 - date of revision
Updated on 05 October 2022
File name
ieukni-spc-dovato-issue14draft1-clean.pdf
Reasons for updating
- Change to section 4.6 - Pregnancy and lactation
- Change to section 10 - Date of revision of the text
Legal category:Product subject to restricted prescription (C)
Updated on 22 September 2022
File name
ieukni-spc-dovato-issue13draft1-clean.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category:Product subject to restricted prescription (C)
Updated on 22 September 2022
File name
ieukni-pl-dovato-issue10draft1-clean.pdf
Reasons for updating
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 16 June 2022
File name
ieukni-spc-dovato-issue12draft1-clean.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.6 - Pregnancy and lactation
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category:Product subject to restricted prescription (C)
Updated on 16 June 2022
File name
ieukni-pl-dovato-issue9draft1-clean.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - pregnancy, breast feeding and fertility
Updated on 24 February 2022
File name
ieukni-spc-dovato-issue11draft1.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category:Product subject to restricted prescription (C)
Free text change information supplied by the pharmaceutical company
Update of section 4.8 of the SmPC to add “completed suicide” to the list of adverse drug reactions (ADRs) with frequency ”rare”. |
Updated on 24 February 2022
File name
ieukni-pl-dovato-issue8draft1.pdf
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 02 December 2021
File name
ieukni-spc-dovato-issue10draft1.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category:Product subject to restricted prescription (C)
Updated on 02 December 2021
File name
ieukni-pl-dovato-issue7draft1.pdf
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 07 September 2021
File name
ieukni-pl-dovato-issue6draft1.pdf
Reasons for updating
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
update to the details MAH LOC representatives
Updated on 07 September 2021
File name
ieukni-spc-dovato-issue9draft1.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 10 - Date of revision of the text
Legal category:Product subject to restricted prescription (C)
Free text change information supplied by the pharmaceutical company
Section 4.1, 4.4, 5.2 - update to lamivudine (3TC) dose with a creatinine clearance (CLcr) ≥30 milliliters (mL)/minute (min) update to lamivudine (3TC) dose with a creatinine clearance (CLcr) ≥30 milliliters (mL)/minute (min)
Section 6.6 - QRD update
Updated on 23 August 2021
File name
ie-spc-dovato-issue8draft1-clean.pdf
Reasons for updating
- Change to section 6.3 - Shelf life
- Change to section 10 - Date of revision of the text
Legal category:Product subject to restricted prescription (C)
Free text change information supplied by the pharmaceutical company
Update to Section 6.3: shelf life extenion from 24 months to 36 months
Updated on 25 May 2021
File name
ie-spc-dovato-issue7draft1-clean.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category:Product subject to restricted prescription (C)
Updated on 25 May 2021
File name
ie-pl-dovato-issue5draft1-clean.pdf
Reasons for updating
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 25 November 2020
File name
ie-spc-dovato-issue6draft1.pdf
Reasons for updating
- Change to section 4.6 - Pregnancy and lactation
Legal category:Product subject to restricted prescription (C)
Free text change information supplied by the pharmaceutical company
- update relating to the Breast-feeding sub-section of section 4.6 of the SmPC
Updated on 30 July 2020
File name
ie-pl-dovato-issue4draft1.pdf
Reasons for updating
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
section 2: update to the pregnancy information in relation to the occurrence of neural tube defects (NTD) with the DTG regimens
Section 4: update to add information regarding weight, blood lipid and blood glucose effects following
Section 6: update to the approval date
Updated on 30 July 2020
File name
ie-pl-dovato-issue4draft1.pdf
Reasons for updating
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
Section 2: update to the pregnancy information in relation to the occurrence of neural tube defects (NTD) with the DTG regimens
Section 4: update to include information regarding weight, blood lipid and blood glucose effects
Section 6: update to the approval date
Updated on 30 July 2020
File name
ie-spc-dovato-issue5draft1.pdf
Reasons for updating
- Change to section 4.6 - Pregnancy and lactation
- Change to section 10 - Date of revision of the text
Legal category:Product subject to restricted prescription (C)
Free text change information supplied by the pharmaceutical company
section 4.6: update to the pregnancy information in relation to the occurrence of neural tube defects (NTD) with the DTG regimens
Section 10: update to the approval date
Updated on 02 June 2020
File name
ie-spc-dovato-issue4draft1.pdf
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category:Product subject to restricted prescription (C)
Free text change information supplied by the pharmaceutical company
Change of the address of the marketing authorisation holder. ViiV Healthcare BV Limited will be moving from their current location in Huis ter Heideweg 62, 3705 LZ Zeist, The Netherlands to the company's new address Van Asch van Wijckstraat 55H, 3811 LP Amersfoort.
Updated on 02 June 2020
File name
ie-pl-dovato-issue3draft1.pdf
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
Change of the address of the marketing authorisation holder. ViiV Healthcare BV Limited will be moving from their current location in Huis ter Heideweg 62, 3705 LZ Zeist, The Netherlands to the company's new address Van Asch van Wijckstraat 55H, 3811 LP Amersfoort.
Updated on 21 April 2020
File name
ie-spc-dovato-issue3draft1.pdf
Reasons for updating
- Change to section 4.3 - Contraindications
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 10 - Date of revision of the text
- Removal of Black Inverted Triangle
Legal category:Product subject to restricted prescription (C)
Free text change information supplied by the pharmaceutical company
Removal of the Black Triangle
SmPC section 4.3 - addition of a contraindication in relation to co-administration with medicinal products with narrow therapeutic windows, that are substrates of OCT-2, including fampridine.
SmPC section 4.5 - other edits to the interaction section including the removal of drug-drug interactions for products no longer authorised in the EU (boceprevir, dofetilide, nelfinavir).
SmPC section 10 - date of text
Updated on 21 April 2020
File name
ie-pl-dovato-issue2draft1.pdf
Reasons for updating
- Change to section 2 - what you need to know - contraindications
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 4 - how to report a side effect
- Change to section 6 - date of revision
- Removal of Black Inverted Triangle
Free text change information supplied by the pharmaceutical company
the removal of the black triangle for Dovato
Section 4.3 - addition of a contraindication in relation to co-administration with medicinal products with narrow therapeutic windows, that are substrates of OCT-2, including fampridine.
Section 4.5 - other edits to the interaction section including the removal of drug-drug interactions for products no longer authorised in the EU (boceprevir, dofetilide, nelfinavir).
Section 4.8 - the Irish reporting details for the HPRA have been updated to reflect the update to Appendix V of the QRD template.
Updated on 18 February 2020
File name
ie-spc-dovato-issue2draft1.pdf
Reasons for updating
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 5.1 - Pharmacodynamic properties
Legal category:Product subject to restricted prescription (C)
Updated on 05 November 2019
File name
ie-spc-dovato-issue1draft1 - for medicines.ie.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to restricted prescription (C)
Free text change information supplied by the pharmaceutical company
MAA approved on the 1 July 2019
Updated on 05 November 2019
File name
ie-pl-dovato-issue1draft1 - for medicines.ie.pdf
Reasons for updating
- New PIL for new product
Free text change information supplied by the pharmaceutical company
New MAA licenced in July 2019